Keyword: Bristol-Myers Squibb
Roche has the pipeline it needs for growth, its chairman said, but the company could add on with small- or medium-sized M&A.
Merck's latest additions to the multichannel "It's Tru" campaign for cancer drug Keytruda include two TV ads featuring a real oncologist.
Exelixis nabbed an FDA nod for Cabometyx in second-line liver cancer, where Stivarga, Opdivo and Keytruda are already battling it out.
Past pharma mergers have spawned price hikes, two U.S. representatives argue—and DTC and DOJ need to weigh the $74 billion deal with that in mind.
Patients using copay coupons were more likely to stay on their drugs longer, but the vouchers didn't help with outcomes, a new study found.
It wasn't just deals folks were buzzing about in meeting rooms, restaurants and hotel lobbies, as our top FierceBiotech and FiercePharma stories show.
Pharma came storming out of the gate at this year's J.P. Morgan meeting in a Monday full of deal talk, CEO ambitions and analyst prognostications.
CEOs for BMS and Celgene took to the J.P. Morgan Healthcare Conference to explain the rationale for their $74 billion megadeal.
Thanks to new severance deals for top executives, it’s not only Celgene investors who are set for a big payoff with this week’s $74 billion sale to Bristol-Myers Squibb.
New cancer drugs in the BMS-Celgene pipeline won't be enough to cover an earlier-than expected Revlimid patent loss, analysts say.